Related Experiment Video

Updated: Apr 25, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

1.2K

Therapeutic potential of siRNA and DNAzymes in cancer

Hanuma Kumar Karnati1, Ravi Shekar Yalagala, Rambabu Undi

  • 1Hematologic Oncology, Stem Cells and Blood Disorders Laboratory, Department of Biochemistry, School of Life Sciences, University of Hyderabad, (PO) Gachibowli, Hyderabad, AP, 500046, India.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine
|August 24, 2014
PubMed

Insights

Antisense technologies like small interfering RNAs (siRNAs) and DNAzymes offer promising cancer therapeutics by targeting gene expression. Overcoming delivery challenges is key to their clinical success in cancer treatment.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Cancer remains a global health threat due to uncontrolled cell growth, invasion, and metastasis.
  • Current cancer treatments (surgery, chemotherapy, radiotherapy) have limitations and do not cure all cancers.
  • The molecular mechanisms of cancer progression are not fully understood, hindering effective treatment development.

Purpose of the Study:

  • To review the potential of antisense molecules, specifically small interfering RNAs (siRNAs) and DNAzymes, in cancer therapeutics.
  • To discuss the challenges associated with the in vivo delivery of siRNAs for cancer treatment.
  • To highlight the potential of DNAzymes in cancer therapy due to their selectivity and catalytic efficiency.

Main Methods:

  • Review of current literature on antisense technologies in cancer research.
  • Analysis of the mechanisms of action for siRNAs and DNAzymes in targeting cancer-associated genes.
  • Exploration of delivery strategies and challenges for nucleic acid-based therapeutics.

Main Results:

  • siRNAs show promise in downregulating cancer-associated genes but face significant in vivo delivery obstacles.
  • DNAzymes exhibit high selectivity and catalytic efficiency, presenting a strong potential for cancer treatment.
  • Advances in antisense technology offer new tools for investigating and targeting cancer pathways.

Conclusions:

  • siRNAs and DNAzymes represent promising avenues for developing novel cancer therapeutics.
  • Addressing the in vivo delivery challenges is crucial for the successful clinical application of siRNA and DNAzyme-based cancer treatments.
  • Further research into antisense molecule delivery systems is warranted to fully realize their therapeutic potential in oncology.

More Related Videos

DNA Vector-based RNA Interference to Study Gene Function in Cancer13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

19.7K
TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents09:18

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

Published on: June 2, 2016

5.3K

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
13.4K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.9K
RNA Interference01:23

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
24.3K